Hairy cell leukemia variant: fact or fiction.

Department of Pathology, University of Utah, Salt Lake City, 84132, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 02/2005; 123(1):132-8.
Source: PubMed

ABSTRACT Hairy cell leukemia variant (HCL-V) is a poorly described, rare B-cell lymphoproliferative disorder typically positive for CD103 and CD11c, while lacking CD25. Splenic marginal zone lymphomas (SMZL) also have this unusual phenotype in 15% to 25% of cases, have other overlapping clinical or morphologic features, and are more common than HCL-V. The purpose of our study was to better characterize HCL-V and determine whether most cases could be distinguished from SMZL. Cases with an HCL-V phenotype were identified from our flow cytometry service, and 10 were selected for further study based on bone marrow or splenic tissue availability. All cases had cytologic features consistent with HCL-V, and 9 of 10 patients had lymphocytosis. Bone marrow involvement was mostly interstitial and/or sinusoidal without lymphoid nodules. Coexpression of preswitched with postswitched heavy chain isotypes, an unusual feature of HCL, was seen in 2 of 4 cases. This study better defines HCL-V and establishes that most cases do not represent SMZL.

Download full-text


Available from: Sheryl R Tripp, Sep 28, 2015
132 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hairy cell leukemia-variant (HCL-V) is an extremely rare chronic B-cell lymphoproliferative disorder clinically and morphologically distinct from classic hairy cell leukemia (HCL). HCL-V is thought to represent a hybrid between prolymphocytic leukemia and HCL, the nucleus more closely resembling a prolymphocyte and the cytoplasm a hairy cell. The clinical course of HCL-V is aggressive with short survivals. Since single courses of cladribine have profound activity in HCL, inducing durable complete responses in 91% of patients, we administered cladribine to 4 patients with HCL-V over a 7-year period. During this time interval 357 patients with classic HCL received cladribine at Scripps Clinic. Each patient received cladribine at 0.1 mg/kg per day by continuous intravenous infusion for 7 days, repeated at 28-day intervals depending on response status. The 4 patients ranged in age from 28 to 70. Two presented with B-symptoms, 1 had peripheral adenopathy, and all 4 displayed massive splenomegaly. Peripheral blood counts were notable for lymphocytosis associated with mild anemia and thrombocytopenia. Only 1 of the 4 patients had received prior treatment. Peripheral blood immunophenotypic analysis revealed monoclonal B cells with expression of CD11c in 3 patients, lack of CD25 expression in 3 patients and expression of CD103 in all but 1 patient. The number of cladribine courses administered ranged from two to five. Of these 4 patients, 1 (25%) achieved a complete response and 2 (50%) partial responses, for an overall response rate of 75%. Three patients underwent splenectomy after cladribine. Cladribine is an active agent in HCL-V albeit with a lower response rate than in classic HCL. The role of other treatment modalities, such as splenectomy, interferon-alpha, and 2'-deoxycoformycin, alone or in combination with cladribine awaits further evaluation.
    Leukemia and Lymphoma 11/1999; 35(3-4):347-54. DOI:10.3109/10428199909145739 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three patients with B-prolymphocytic variant of HCL (HCL-V) were treated with a chlorinated purine analogue, 2-chlorodeoxyadenosine, at a daily dosage of 0.12 mg/kg in 2-hour intravenous infusion for 5 consecutive days. Partial remission was achieved in only 1 patient, who relapsed after 6 months. Two other patients did not respond to the treatment. HCL-V is a distinct clinicopathological entity which seems to be resistant to various therapeutic modalities. However, further observations are necessary in order to establish the efficacy of 2-CdA in the treatment of HCL-V.
    Leukemia and Lymphoma 05/1997; 25(3-4):381-5. DOI:10.3109/10428199709114177 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Splenic lymphoma with villous lymphocytes (SLVL) represents a low-grade B-cell non-Hodgkin's lymphoma (NHL) that histologically is indistinguishable from splenic marginal-zone lymphoma (SMZL). Characteristic features of SLVL are splenomegaly, moderate lymphocytosis, nodular and intrasinusoidal pattern of bone marrow infiltration, serum monoclonal band, slow benign course, and response to splenectomy. The diagnosis is made by the morphology of the circulating villous cells and their immunophenotype, which is distinct from that of chronic lymphocytic leukemia (CLL) and hairy-cell leukemia (HCL), diseases with which SLVL may be confused. When treatment is indicated, splenectomy is the treatment of choice, but some patients may require additional chemotherapy to control progression. In those circumstances, fludarabine may be the agent of choice. Despite its unique features, which, compounded, suggest that SLVL is a clinicopathologic entity, there are no specific chromosome abnormalities and problems of differential diagnosis with other B-cell NHLs, chiefly mantle-cell lymphoma (MCL), remain in a minority of patients.
    Seminars in Hematology 05/1999; 36(2):148-54. · 3.27 Impact Factor
Show more